Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Other Non Operating Income (2016 - 2020)

Soleno Therapeutics (SLNO) has disclosed Other Non Operating Income for 8 consecutive years, with $1000.0 as the latest value for Q3 2020.

  • For Q3 2020, Other Non Operating Income fell 96.55% year-over-year to $1000.0; the TTM value through Sep 2020 reached $34000.0, down 79.01%, while the annual FY2023 figure was $2.6 million, 759.33% up from the prior year.
  • Other Non Operating Income hit $1000.0 in Q3 2020 for Soleno Therapeutics, roughly flat from $1000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $1.1 million in Q1 2016 and bottomed at -$672000.0 in Q1 2017.
  • Average Other Non Operating Income over 5 years is $59131.4, with a median of $21000.0 recorded in 2019.
  • Year-over-year, Other Non Operating Income crashed 162.57% in 2017 and then soared 766.67% in 2018.
  • Soleno Therapeutics' Other Non Operating Income stood at $411497.0 in 2016, then crashed by 98.78% to $5000.0 in 2017, then soared by 480.0% to $29000.0 in 2018, then dropped by 27.59% to $21000.0 in 2019, then crashed by 95.24% to $1000.0 in 2020.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at $1000.0, $1000.0, and $11000.0 for Q3 2020, Q2 2020, and Q1 2020 respectively.